Viking Therapeutics (NASDAQ:VKTX) Rating Increased to Strong-Buy at Raymond James
Raymond James upgraded shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) from an outperform rating to a strong-buy rating in a research note published on Thursday morning, MarketBeat.com reports. Raymond James currently has $116.00 price objective on the biotechnology company’s stock, up from their previous price objective of $115.00. VKTX has been the topic of […]